Pluristem Therapeutics (PSTI) Stock Analysis

What Pluristem Therapeutics does

Pluristem Therapeutics Inc., an Israeli biotechnology firm founded in 2001 and based in Haifa, specializes in the discovery, advancement, clinical assessment, and production of innovative cell-based therapeutic products. The company's primary focus is on addressing a spectrum of severe medical conditions, including those related to reduced blood flow (ischemia), inflammation, blood disorders, and autoimmune dysfunctions, using its proprietary technologies. A cornerstone of their product pipeline involves placental expanded (PLX) based cell therapies. Their leading investigational drug, PLX-PAD, is currently undergoing evaluation in several clinical studies: it's in a late-stage (Phase III) trial to aid recovery after hip fracture surgery, a mid-stage (Phase II) trial for treating acute respiratory distress syndrome linked to COVID-19, and an early-to-mid-stage (Phase I/II) trial for severe graft-versus-host disease that has not responded to steroid treatment. Another significant product, PLX-R18, has successfully completed its initial Phase I clinical trial for individuals experiencing incomplete blood cell recovery following hematopoietic cell transplantation. Additionally, Pluristem is conducting preclinical animal studies to investigate PLX-R18's potential for treating acute radiation syndrome. The company also engages in various strategic collaborations: it holds a licensing agreement that facilitates PLX-PAD clinical trials in South Korea; participates in the nTRACK project, which explores labeling stem cells with gold nanoparticles; and has a unique partnership with NASA's Ames Research Center to assess how PLX cell therapies might prevent or alleviate medical issues encountered during space missions.

Key metrics

ETFs linked to PSTI

Broad-market and Healthcare sector ETFs an investor holding Pluristem Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how PSTI fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Pluristem Therapeutics?

Pluristem Therapeutics trades under the ticker PSTI on NASDAQ.

Which exchange is PSTI listed on?

PSTI is listed on NASDAQ.

What sector does Pluristem Therapeutics operate in?

Pluristem Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze PSTI in a portfolio?

PortView shows PSTI's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.